You can buy or sell FOLD and other stocks, options, ETFs, and crypto commission-free!
Amicus Therapeutics, Inc. engages in the discovery, developmen0t, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. Read More The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
Cranbury, New Jersey
52 Week High
52 Week Low
Seeking AlphaMay 23
Amicus Therapeutics: Galafold Doing Better Than Q1 Revenues Suggest
The company added 150 new patients in Q1, more than the total number of patients treated in the first twelve months of the EU launch.
Yahoo FinanceMay 10
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
CRANBURY, N.J., May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14, 2019 at 1:00 p.m. PT. A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations , and will be...
Yahoo FinanceMay 9
Amicus' Earnings & Revenues Miss Estimates in Q1
Amicus Therapeutics, Inc. FOLD reported loss of 39 cents per share in the first quarter of 2019 (excluding loss on exchange of convertible notes), wider than the year-ago loss of 28 cents and the Zacks Consensus Estimate of a loss of 31 cents. Total revenues in the first quarter were $34 million, reflecting 104% surge from $16.7 million in the year-ago quarter. The figure missed the Zacks Consensus Estimate of $38 million. The company realized revenues from commercial sales of its only marketed drug, Galaf...
Expected Aug 7, Pre-Market